ECSP22038978A - INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA - Google Patents

INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA

Info

Publication number
ECSP22038978A
ECSP22038978A ECSENADI202238978A ECDI202238978A ECSP22038978A EC SP22038978 A ECSP22038978 A EC SP22038978A EC SENADI202238978 A ECSENADI202238978 A EC SENADI202238978A EC DI202238978 A ECDI202238978 A EC DI202238978A EC SP22038978 A ECSP22038978 A EC SP22038978A
Authority
EC
Ecuador
Prior art keywords
alpha4ß7
inhibition
human integrin
integrin
human
Prior art date
Application number
ECSENADI202238978A
Other languages
English (en)
Inventor
Bryce A Harrison
Evelyne Houang
Salma Rafi
Robert Zahler
Cheng Zhong
fu-yang Lin
Aleksey I Gerasyuto
Tyler Day
Byungchan Kim
Bruce N Rogers
James E Dowling
Blaise S Lippa
Eugene Hickey
Dan Cui
Kyle D Konze
Dawn M Troast
Kristopher N Hahn
Matthew G Bursavich
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of ECSP22038978A publication Critical patent/ECSP22038978A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Moléculas pequeñas antagonistas de la integrina humana Alfa4ß7, y métodos para usarlas en el tratamiento de varias enfermedades y afecciones.
ECSENADI202238978A 2019-10-16 2022-05-16 INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA ECSP22038978A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16

Publications (1)

Publication Number Publication Date
ECSP22038978A true ECSP22038978A (es) 2022-06-30

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202238978A ECSP22038978A (es) 2019-10-16 2022-05-16 INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA

Country Status (37)

Country Link
US (3) US11104661B1 (es)
EP (3) EP4045039B1 (es)
JP (7) JP7437490B2 (es)
KR (2) KR20220102669A (es)
CN (3) CN115087444B (es)
AR (1) AR120244A1 (es)
AU (2) AU2020366435A1 (es)
BR (1) BR112022007284A2 (es)
CA (1) CA3154269A1 (es)
CL (1) CL2022000959A1 (es)
CO (1) CO2022005759A2 (es)
CR (1) CR20220205A (es)
CU (1) CU20220027A7 (es)
DK (1) DK4045039T3 (es)
DO (2) DOP2022000081A (es)
EC (1) ECSP22038978A (es)
ES (1) ES3035561T3 (es)
FI (1) FI4045039T3 (es)
HR (1) HRP20250749T1 (es)
HU (1) HUE071814T2 (es)
IL (2) IL319053A (es)
LT (1) LT4045039T (es)
MA (1) MA57399B1 (es)
MD (1) MD4045039T2 (es)
MX (1) MX2022004406A (es)
PE (1) PE20221829A1 (es)
PH (1) PH12022550886A1 (es)
PL (1) PL4045039T3 (es)
PT (1) PT4045039T (es)
PY (1) PY2065718A (es)
RS (1) RS66976B1 (es)
SI (1) SI4045039T1 (es)
TW (7) TWI857592B (es)
UA (1) UA130059C2 (es)
UY (1) UY38926A (es)
WO (3) WO2021076902A1 (es)
ZA (2) ZA202203872B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773573B1 (en) 2018-04-12 2026-03-18 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
CA3139526A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
JP7437490B2 (ja) * 2019-10-16 2024-02-22 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
US20250195485A1 (en) * 2021-12-27 2025-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and medical use thereof
TW202416966A (zh) 2022-09-09 2024-05-01 大陸商西藏海思科製藥有限公司 丙酸衍生物及其在醫藥上的應用
EP4638438A1 (en) 2022-12-22 2025-10-29 Xinthera, Inc. Alpha4 beta7 integrin antagonists and uses thereof
EP4669637A1 (en) * 2023-02-21 2025-12-31 C4x Discovery Limited ALPHA4BETA7 MACROCYCLIC INHIBITORS
CN121335980A (zh) 2023-05-26 2026-01-13 阿达尔克斯制药有限公司 Sod1调节组合物及其使用方法
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN121712771A (zh) 2023-07-28 2026-03-20 上海翰森生物医药科技有限公司 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
CN119504796B (zh) * 2024-11-20 2026-03-10 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425431T2 (de) 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
CA2268270A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Heterocyclic derivatives as factor xa inhibitors
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
EP1034164B1 (en) 1997-11-24 2004-05-19 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2333647A1 (en) 1998-06-29 2000-01-06 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
EP1189881B2 (en) * 1999-05-07 2013-01-23 Encysive Pharmaceuticals, Inc. Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
JP2003509488A (ja) 1999-09-24 2003-03-11 ジェネンテック・インコーポレーテッド チロシン誘導体
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
EP1313705A1 (en) * 2000-08-30 2003-05-28 Pharmacia Corporation Gem-substituted alpha v beta 3 integrin antagonists
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
HUE058817T2 (hu) 2004-09-03 2022-09-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
WO2006112951A2 (en) 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
BRPI0611243A2 (pt) 2005-06-09 2010-08-24 Ucb Pharma Sa composto, enanciâmeros, diastereoisâmeros do mesmo ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
EP3412309A1 (en) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Methods of administering beta7 integrin antagonists
HK1213522A1 (zh) 2012-10-05 2016-07-08 F. Hoffmann-La Roche Ag 用於诊断和治疗炎性肠病的方法
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
WO2016086147A1 (en) * 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
CA2972099A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
IL316954A (en) * 2017-02-28 2025-01-01 Morphic Therapeutic Inc (Alpha-V)(beta-6)integrin inhibitors
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
EP3773573B1 (en) 2018-04-12 2026-03-18 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
JP7437490B2 (ja) * 2019-10-16 2024-02-22 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリン（アルファ－４）（ベータ－７）の阻害

Also Published As

Publication number Publication date
TWI840047B (zh) 2024-04-21
KR20230088376A (ko) 2023-06-19
MX2022004406A (es) 2022-08-25
WO2021076902A1 (en) 2021-04-22
JP7500785B2 (ja) 2024-06-17
CR20220205A (es) 2022-07-22
CU20220027A7 (es) 2022-12-12
CN115087444A (zh) 2022-09-20
JP7209116B2 (ja) 2023-01-19
JP2024054293A (ja) 2024-04-16
UA130059C2 (uk) 2025-10-29
UY38926A (es) 2021-05-31
JP2024054296A (ja) 2024-04-16
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
CN116783161A (zh) 2023-09-19
TWI888065B (zh) 2025-06-21
EP4559525A3 (en) 2025-08-20
EP4045039B1 (en) 2025-04-23
PY2065718A (es) 2023-01-17
TW202244040A (zh) 2022-11-16
ZA202303992B (en) 2024-06-26
DOP2022000081A (es) 2022-07-31
IL292296B1 (en) 2025-03-01
CA3154269A1 (en) 2021-04-22
CN119192137A (zh) 2024-12-27
CN115087444B (zh) 2024-09-17
JP2022548809A (ja) 2022-11-22
LT4045039T (lt) 2025-08-11
ES3035561T3 (en) 2025-09-04
TW202332675A (zh) 2023-08-16
US11370773B1 (en) 2022-06-28
PL4045039T3 (pl) 2025-09-15
JP2023036958A (ja) 2023-03-14
JP2023500437A (ja) 2023-01-06
MA57399B1 (fr) 2025-06-30
CL2022000959A1 (es) 2023-04-28
HUE071814T2 (hu) 2025-09-28
DOP2025000034A (es) 2025-04-08
KR20220102669A (ko) 2022-07-20
SI4045039T1 (sl) 2025-07-31
JP7437490B2 (ja) 2024-02-22
IL319053A (en) 2025-04-01
TW202126624A (zh) 2021-07-16
EP4045039A4 (en) 2023-12-13
EP4228634A4 (en) 2024-12-18
PE20221829A1 (es) 2022-11-29
AU2021361031A1 (en) 2023-06-08
EP4045039A1 (en) 2022-08-24
WO2022081983A1 (en) 2022-04-21
CO2022005759A2 (es) 2022-05-20
WO2021076890A1 (en) 2021-04-22
JP2024116230A (ja) 2024-08-27
HRP20250749T1 (hr) 2025-08-15
FI4045039T3 (fi) 2025-06-20
TWI900200B (zh) 2025-10-01
BR112022007284A2 (pt) 2022-07-05
AR120244A1 (es) 2022-02-09
EP4559525A2 (en) 2025-05-28
JP7437495B2 (ja) 2024-02-22
MD4045039T2 (ro) 2025-11-30
IL292296A (en) 2022-06-01
PH12022550886A1 (en) 2023-05-03
JP2022542184A (ja) 2022-09-29
ZA202203872B (en) 2024-01-31
TW202315868A (zh) 2023-04-16
US11104661B1 (en) 2021-08-31
TW202500558A (zh) 2025-01-01
JP7702004B2 (ja) 2025-07-02
TWI802477B (zh) 2023-05-11
IL292296B2 (en) 2025-07-01
JP7717202B2 (ja) 2025-08-01
EP4228634A1 (en) 2023-08-23
AU2020366435A1 (en) 2022-04-21
WO2021076890A4 (en) 2021-06-10
PT4045039T (pt) 2025-07-02
TWI775182B (zh) 2022-08-21
RS66976B1 (sr) 2025-07-31
TWI791304B (zh) 2023-02-01
TW202500559A (zh) 2025-01-01
US20240174632A1 (en) 2024-05-30
DK4045039T3 (da) 2025-06-30

Similar Documents

Publication Publication Date Title
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
UY38353A (es) Inhibición de integrina alfavbeta6
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2024008096A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX2022009056A (es) Inhibidores de integrina ?v?6.
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MX374501B (es) Formulaciones de anticuerpos de her2 subcutáneas.
SV2018005610A (es) Derivados de oxopiridina sustituidos
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2013000047A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20130058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20130074A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY38352A (es) Inhibidores de integrina alfavbeta6
CL2015002835A1 (es) Nuevos derivados de piridina
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
EP3625245A4 (en) PEPTIDIC COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES
EP3585818A4 (en) ANTI-HLA-DQ2.5 / 8 ANTIBODIES AND ITS USE FOR THE TREATMENT OF C LIATIC DISEASE
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.